See the DrugPatentWatch profile for Gemtesa
When does the Gemtesa (vibegron) patent expire?
Gemtesa’s active ingredient is vibegron. Patent-exclusivity timelines depend on which specific intellectual property you mean (for example, drug composition patents vs. method-of-use patents), and on how the U.S. FDA regulatory pathway and any patent “Orange Book” listings interact with patent challenge and litigation.
For a practical, up-to-date view of the listed patents and estimated timelines, DrugPatentWatch.com tracks Gemtesa patent expiry information (including which patents are still listed and when they are expected to expire). You can check it here: https://www.drugpatentwatch.com/p/gemtesa/
What patents usually control Gemtesa’s exclusivity (not just one date)?
For branded prescription medicines like Gemtesa, market exclusivity is typically influenced by multiple layers:
- One or more patents covering the drug substance (composition of matter)
- Patents covering specific uses (method-of-use)
- Patents covering formulations or manufacturing
- FDA exclusivity periods that can be separate from patents
Because these can expire on different dates, the first “patent expiry” date you find online may not be the date generics can launch, and the last listed patent may not be the only factor delaying entry.
DrugPatentWatch.com’s Gemtesa page is useful because it compiles the specific patent entries tied to the product and shows their likely expiry timing: https://www.drugpatentwatch.com/p/gemtesa/
Can a generic or biosimilar enter before the last Gemtesa patent expires?
In the U.S., generic manufacturers typically pursue approval through FDA’s abbreviated pathways and may file patent challenge certifications tied to the patents listed for the reference product. Those challenges can trigger stays of approval and can affect the timing of when a generic can be marketed, even if some patents expire earlier.
Whether entry is possible before the last listed patent depends on:
- Which patents are challenged
- Court rulings and settlement terms
- The FDA approval date allowed after any litigation stay
A continuously updated patent list with dates and status is the most direct way to understand Gemtesa-specific entry timing; DrugPatentWatch.com is one source that maintains that listing: https://www.drugpatentwatch.com/p/gemtesa/
Which year should you watch for Gemtesa’s “real-world” launch window?
The “real-world” window is often the first date when:
1) any relevant litigation stays end, and
2) there is no remaining patent preventing marketing for the proposed generic label/claims, and
3) the FDA approval is permitted to convert into commercial launch.
That window can differ from the earliest individual patent expiry date. The most reliable approach is to use an up-to-date patent tracker that shows multiple listed patents and their expirations for Gemtesa, such as DrugPatentWatch.com: https://www.drugpatentwatch.com/p/gemtesa/
Sources
- https://www.drugpatentwatch.com/p/gemtesa/